STAT
@statnews
Reporting from the frontiers of health & medicine.
Sign up for any of our newsletters here:
4.7K Following 165.5K Followers
The FDA warned that GLP-1 drugs carry a potential risk for a rare but serious eye condition and required pharma companies to inform patients and doctors of the risk.
A House lawmaker asked the Government Accountability Office to review whether the TrumpRx platform has saved Americans any money.
As Epic’s dominance grows, its iron grip is choking innovation in health technology
Kennedy and his MAHA movement have embraced peptides, though there's little evidence for many of the wellness compounds.
In this edition of AI Prognosis: A new investigation into how Epic's market dominance is impacting health tech innovation and AI adoption.
Join STAT reporters Adam Feuerstein, Andrew Joseph, and Katherine MacPhail for ESMO 2026: The STAT Recap, a live breakdown of the biggest news and data from Europe’s premier oncology meeting. Get STAT’s take on the findings & developments that matter most.
📅 Tomorrow @ 10 a.m.
Show more
El-Sayed on RFK Jr.'s to @AnilOza16:
"[I]t’s ironic to hear a guy who’s trafficked in eugenicist terms, who rejects science outright ... lecture voters about an Arab American scientist with two doctoral degrees who believes in science, like vaccines.”
Show more
Abdul El-Sayed has made headlines for his progressive politics and stance on Israel. But some supporters consider his public health background critical.
#News#: Senate candidate El-Sayed wants to ‘grill’ RFK Jr., calls him the ‘most incompetent HHS secretary ever’
Missouri attorney general warned Eli Lilly to discontinue requiring hospitals to provide claims data to receive discounted medicines under 340B program
Eli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.
Show more
New investigation from @statnews:
Epic's control over access to hospitals' health data means that it is picking and choosing winners in health tech and AI, and can throttle access to those it deems unworthy, or competitive with its own products.
Show more
In a large diabetes study, Eli Lilly's investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic.
However, questions remain about long-term safety. More details here:
Show more
After years of steep increases, especially amid the pandemic, U.S. overdose deaths decreased 27% in 2024, and preliminary data from 2025 show another meaningful drop.
Data add to expectations that the drug will be one of Lilly’s greatest growth drivers.
STAT is looking to learn, from people with direct knowledge, how Epic's actions impact hospitals' technology choices. Share your story with us.
“A few years ago, I froze my eggs — and the experience was anything but empowering,” writes physician Pooja Yerramilli.
#STATSummit# week is here. More than 400 leaders will be in the room in Boston, with hundreds more joining online.
Don’t miss two days of live conversations with the people at the center of this year’s biggest stories. There’s still time to join us:
Show more
Just 40 percent of Americans reported a lot of confidence in U.S. hospitals and health clinics, the same proportion as in Portugal and Uruguay.
In a letter, 12-year-old Brecken urged Novartis to make the Duchenne therapy he received available to patients like his friend Yannick:
"It is getting hard for him to throw the ball for his dog Rosie and drink a glass of water. This makes me sad."
Show more
